Fresenius Medical Care AG & Co. KGaA (ADR) (NYSE:FMS)

CAPS Rating: 5 out of 5

The Company is engaged in the manufacture and sale of products for all forms of kidney dialysis, to health care providers throughout the world, and in providing kidney dialysis treatment and other medical ancillary services.

Results 1 - 20 of 23 : 1 2 Next »

Recs

0
Member Avatar NHWeston102 (61.88) Submitted: 3/12/2014 11:28:42 AM : Outperform Start Price: $32.98 FMS Score: -4.19

FRS is in the tragic business of serving those who need dialysis, a community that multiplies every day. Although Buffet's enthusiasm for DaVita has left them in the shadows, FRS is larger, better funded, global, and the stock is less expensive.

Recs

5
Member Avatar valuemoney (99.99) Submitted: 8/14/2013 11:48:54 PM : Outperform Start Price: $32.68 FMS Score: -15.71

Retained earnings growth.... if anyone knows what that is. Margins have steadily been improving over the last ten years. ROE and ROI will increase also. The market has beat this equity by a large margin over the last two years, at current prices I think this will change over the next 2 to 5 years. I love my chances of this equity outperforming the S&P.

Recs

0
Member Avatar HTNDOC (< 20) Submitted: 7/11/2013 3:51:31 PM : Outperform Start Price: $31.61 FMS Score: -11.38

I work in the industry and buying contrarian. There will be cuts in dialysis reimbursement, but it won't be 10%. The profit margins will continue to be about the same as they are now.

Recs

0
Member Avatar TrackFortune2013 (64.71) Submitted: 1/3/2013 3:31:51 PM : Outperform Start Price: $34.35 FMS Score: -43.26

Fresenius Medical Care A.G. (NYSE: FMS) was also selected due to it being a dialysis winner here in the U.S. At $35.10, its 52-week range is $31.79 to $39.10 and its market cap is about $21.5 billion. Fresenius yields only 0.9% and its recent adjustment for a 2-for-1 stock split implies an expected upside of roughly 7%.

Recs

0
Member Avatar BrianStocks (39.48) Submitted: 9/23/2009 2:12:00 PM : Outperform Start Price: $23.67 FMS Score: -42.54

follows the market~~

Recs

0
Member Avatar smoke14 (< 20) Submitted: 6/5/2009 1:31:24 PM : Outperform Start Price: $20.08 FMS Score: -44.34

Dialysis treatment will continue to expand

Recs

0
Member Avatar WilliamCrook2007 (< 20) Submitted: 11/20/2008 3:08:15 PM : Outperform Start Price: $19.63 FMS Score: -86.96

IBD

Recs

0
Member Avatar emeraldinv (36.46) Submitted: 11/8/2008 3:35:46 PM : Outperform Start Price: $20.75 FMS Score: -51.44

Regular profit gain over last several years continued through 2008. Expect improving profits to continue with expanding health care.

Recs

0
Member Avatar Salamatgod (< 20) Submitted: 5/17/2008 10:00:45 PM : Outperform Start Price: $25.57 FMS Score: -12.44

IS A PLUS

Recs

2
Member Avatar jjayzzone (< 20) Submitted: 5/12/2008 4:50:06 PM : Outperform Start Price: $25.49 FMS Score: -14.45

My company is working on the expansion of the Fresenius site in Ogden, Utah. In the simplest terms, there are now six lines producing the "fibers" used in the dialysis equipment. There are more lines to come, oh yes, there are more....which means there will be more production. This company is only growing, and I know this from first hand experience.

Recs

1
Member Avatar ThatGuy73 (77.77) Submitted: 5/1/2008 3:46:29 PM : Outperform Start Price: $24.49 FMS Score: -8.90

I've never been good at picks in the medical sector. I like this company for its investment in Renal Solutions, since I can't buy into Renal solutions directly. Here's a blurb about Renal Solutions:

The nature of our new approach -- using living cells as therapeutic agents -- argues for the feasibility of developing whole classes of new cell-based and tissue engineered therapies. The ability to harness vital processes of cells, to target their living molecular machinery on restoring critical substances which have become disordered by disease, has vast implications for the future of medicine. The apparently successful use of living cells in this way validates our approach and should encourage others to investigate cell therapies for a range of disorders.

Recs

0
Member Avatar ChelseaBee (< 20) Submitted: 4/24/2008 9:41:48 AM : Outperform Start Price: $23.75 FMS Score: -7.41

MOre services for the aging population. And the government still pays for dialysis; if they stop (not a chance) this stock may tank.

Recs

0
Member Avatar Brian7992 (56.61) Submitted: 2/19/2008 6:15:54 PM : Outperform Start Price: $23.88 FMS Score: -13.36

I work at a subsidiary of FMS, Spectra Labs. I have no inside info on financials But I like this company and its mission. They treat empolyees well and although we profit from the illness of others we provide important care to them. Our future has never seemed brighter!

Recs

0
Member Avatar bernard08 (46.80) Submitted: 2/19/2008 12:18:58 PM : Outperform Start Price: $23.88 FMS Score: -13.36

Fresenius Medical is well positioned to benefit from its strong market position as a dialysis care provider and product maker. Not only is it the US market leader, it also is growing fast in emerging markets which see rising need for dialysis services.
The company's business model is not exposed to fluctuations in economic growth, and a recent de-rating of its multiples make the stock look like an interesting investment in the longer term.

Recs

0
Member Avatar wallstbusboy (48.02) Submitted: 9/17/2007 9:52:48 PM : Outperform Start Price: $23.90 FMS Score: +0.43

Breaking out to new all time highs after a short period of consolation. Great play on the aging baby boomers and rise in Type II diabetes in this country (sorry for sounding like a rapacious capitalists). Expecting this stock to hit $60 by the end of the year and placing stop loss below the 200 Day Moving Average.

Recs

0
Member Avatar rayrayg (86.65) Submitted: 8/9/2007 6:06:24 PM : Outperform Start Price: $22.67 FMS Score: +6.00

my #.1, 20 to 30% per year

Recs

0
Member Avatar TheGrtGdOM (53.64) Submitted: 7/31/2007 1:42:38 AM : Outperform Start Price: $21.81 FMS Score: +13.36

It's been said. Lots of need with aging boomers and Type2 Diabetes (with resultant renal failure) rising. Small risk that payments may get sqeezed in the future. And safe if the bears take hold. I've actually owned it for a few years in one of my retirement portfolios and it continues to do well. (I like to have stocks that I can leave for decades untouched in there.)

Recs

2
Member Avatar sciencebzzt (28.11) Submitted: 7/22/2007 2:45:30 PM : Outperform Start Price: $21.85 FMS Score: +16.61

My sister-in-law has a small dialysis care company that outsources dialysis nurses. Apparently, all of the equipment they use is Fresenius. She's very happy with the products and the service she's had from them. That got me interested, and after looking over the fundamentals, I bought some shares for my actual portfolio.
Also, this is the largest company that I have in my real portfolio right now.

Recs

0
Member Avatar akalordx (94.13) Submitted: 7/20/2007 11:57:30 AM : Outperform Start Price: $21.16 FMS Score: +23.15

Industry Leader in a field that will only grow in the future. Self sufficient company.

Recs

2
Member Avatar tonysxl1200c (< 20) Submitted: 1/14/2007 10:10:54 PM : Outperform Start Price: $20.49 FMS Score: +16.96

Largest provider of dialysis supplies and services. Nearly self-sufficient company that relies very little on others for services, supplies, or equipment.

Results 1 - 20 of 23 : 1 2 Next »

Featured Broker Partners


Advertisement